BioSpace News Archive

Gilead Sciences, Inc. and Galapagos NV announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16.

Sesen Bio, Inc. announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

Danaher Corporation announced that Daniel L. Comas, Executive Vice President and Chief Financial Officer, and Rainer Blair, Executive Vice President, will be presenting at the Jefferies Global Healthcare Conference.

ImmunoGen, Inc. announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.

CEL-SCI Corporation wants to remind its shareholders that the lower exercise price for its outstanding Series S warrants.

Five Prime Therapeutics, Inc. announced it has entered into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime’s first-in-class investigational drug candidates.

F-star announced that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to acquire the asset-centric vehicle F-star Gamma Ltd (F-star Gamma).

Agilent Technologies, Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire all the business assets of Ultra Scientific.

AbbVie announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018.

Baxter International Inc. announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer.